Loading
Saad Usmani led the pivotal teclistamab study, the first bispecific antibody approved for myeloma.
Saad Z. Usmani is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center. He is a multiple myeloma specialist known for leading MajesTEC-1, the pivotal study of teclistamab that produced the first bispecific antibody approved for myeloma, and for contributing to the daratumumab and ciltacabtagene autoleucel programmes. His selected paper reports teclistamab in relapsed or refractory multiple myeloma. He now chairs the myeloma service at MSK, working on BCMA-directed bispecific T-cell engagers and CAR-T.
| Title | Journal | Year |
|---|---|---|
| Teclistamab in relapsed or refractory multiple myeloma | New England Journal of Medicine | 2022 |
| CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma | The Lancet | 2021 |
| CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint | Nature Medicine | 2025 |
CEPHEUS extends the quadruplet standard to patients who are not going to transplant, closing the gap between transplant-eligible and ineligible populations. It is also one of the first phase 3 trials to be designed around MRD-negativity as the primary endpoint, which could shorten future myeloma trials by years. Frailer patients still need dose-adapted approaches.
CARTITUDE-1 showed that a single CAR-T infusion can put late-stage myeloma into deep, multi-year remission, leading to FDA approval of cilta-cel in 2022 for heavily pretreated disease. It set the efficacy bar for BCMA-directed therapy and motivated moving CAR-T earlier (CARTITUDE-4). Late neurological toxicity and secondary malignancies remain the safety questions.
Shares MajesTEC-1, Teclistamab, BCMA, T-cell engagers (bispecific).
Shares Teclistamab, Daratumumab, T-cell engagers (bispecific), Multiple myeloma.
Shares Teclistamab, Daratumumab, T-cell engagers (bispecific), Multiple myeloma.
Shares Teclistamab, T-cell engagers (bispecific), Multiple myeloma.
Shares Teclistamab, Daratumumab, T-cell engagers (bispecific), Multiple myeloma.
Shares CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma, BCMA, Multiple myeloma.
Shares CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint, Daratumumab, Multiple myeloma.
Shares MajesTEC-1, Teclistamab, BCMA, T-cell engagers (bispecific).